Related Experiment Video
Updated: Mar 30, 2026
07:06
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
27.8K
Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study.
J Theodore Phillips1, April A Erwin2, Stephanie Agrella3
1Baylor Institute for Immunology Research, Dallas, TX, USA. j.theod.phillips@gmail.com.
Neurology and Therapy
|November 4, 2015
Summary
North American clinicians reached consensus on managing gastrointestinal adverse events (GI AEs) for delayed-release dimethyl fumarate (DMF) in multiple sclerosis treatment. Strategies include taking DMF with food and dose adjustments to improve tolerability.
Area of Science:
- Neurology
- Pharmacology
- Clinical Practice
Background:
- Delayed-release dimethyl fumarate (DMF) is a treatment for relapsing multiple sclerosis.
- Gastrointestinal (GI) adverse events (AEs) are common side effects of DMF therapy.
Purpose of the Study:
- To establish consensus among North American clinicians on real-world strategies for managing GI AEs associated with DMF.
- To provide practical guidance for improving DMF tolerability in multiple sclerosis patients.
Main Methods:
- A Delphi process involving two rounds of questionnaires was employed.
- Consensus was defined as agreement by ≥70% of responding clinicians.
Main Results:
- Consensus was achieved on key management strategies for DMF-induced GI AEs.
- Effective strategies include co-administration with food, gradual dose titration, dose reduction, and symptomatic treatments.
Conclusions:
- The consensus strategies offer practical, real-world approaches for clinicians.
- These recommendations aim to enhance the tolerability of DMF in patients with multiple sclerosis.
Related Concept Videos
01:11Oral Drug Delivery Systems: Delayed-Release Systems
144
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
144
01:17Drugs for Treatment of Diarrhea-Predominant IBS
879
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
879
01:29Inflammatory Bowel Disease IV: Pharmacological Management
940
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
940
01:21Drugs for Treatment of Constipation-Predominant IBS
1.2K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.2K
01:26Oral Drug Delivery Systems: Continuous-Release Systems
212
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
212
01:29Drugs for Treatment of Ulcerative Colitis in IBD
627
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
627